Evidence-based medicine and treatment of hypertension in women: Results of trials

Sharonne N. Hayes

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: The aim of this review is to summarize the evidence from randomized controlled trials and meta-analyses of hypertension treatment trials that included women in their study population and subsequent analyses. Results: Most early hypertension treatment trials did not include women in their study population, or did so in insufficient numbers to assess gender-specific outcomes. Women, particularly the elderly, were better represented in subsequent studies, but gender-specific results were not often reported and most trials were not designed or powered to detect gender differences in treatment responses and outcomes. In some studies where gender-specific results have been reported, gender differences have been observed, but the direction of the effect has generally been similar in men and women. Large meta-analyses of treatment trials have found similar relative risk reductions as a result of hypertension treatment, but lower absolute risk reductions in women compared to men. Absolute risk reductions are strongly related to baseline risk and have been demonstrated in virtually all subgroups of women except those with extremely low aggregate cardiovascular risk. While there are still limited data regarding treatment benefits for young women, no subset of women has been shown to experience net harm as a result of hypertension therapy. Conclusion: The design and implementation of future hypertension treatment trials should include the provision to assess gender-specific differences in treatment and outcomes.

Original languageEnglish (US)
JournalJournal of Hypertension
Volume20
Issue numberSUPPL. 2
DOIs
StatePublished - May 2002

Fingerprint

Evidence-Based Medicine
Hypertension
Numbers Needed To Treat
Therapeutics
Meta-Analysis
Risk Reduction Behavior
Population
Randomized Controlled Trials

Keywords

  • Cardiovascular risk
  • Gender
  • Hypertension
  • Meta-analysis
  • Randomized control trial
  • Women

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine

Cite this

Evidence-based medicine and treatment of hypertension in women : Results of trials. / Hayes, Sharonne N.

In: Journal of Hypertension, Vol. 20, No. SUPPL. 2, 05.2002.

Research output: Contribution to journalArticle

@article{15da44dccecd4ee4a0fdbfc7a8877b90,
title = "Evidence-based medicine and treatment of hypertension in women: Results of trials",
abstract = "Purpose: The aim of this review is to summarize the evidence from randomized controlled trials and meta-analyses of hypertension treatment trials that included women in their study population and subsequent analyses. Results: Most early hypertension treatment trials did not include women in their study population, or did so in insufficient numbers to assess gender-specific outcomes. Women, particularly the elderly, were better represented in subsequent studies, but gender-specific results were not often reported and most trials were not designed or powered to detect gender differences in treatment responses and outcomes. In some studies where gender-specific results have been reported, gender differences have been observed, but the direction of the effect has generally been similar in men and women. Large meta-analyses of treatment trials have found similar relative risk reductions as a result of hypertension treatment, but lower absolute risk reductions in women compared to men. Absolute risk reductions are strongly related to baseline risk and have been demonstrated in virtually all subgroups of women except those with extremely low aggregate cardiovascular risk. While there are still limited data regarding treatment benefits for young women, no subset of women has been shown to experience net harm as a result of hypertension therapy. Conclusion: The design and implementation of future hypertension treatment trials should include the provision to assess gender-specific differences in treatment and outcomes.",
keywords = "Cardiovascular risk, Gender, Hypertension, Meta-analysis, Randomized control trial, Women",
author = "Hayes, {Sharonne N.}",
year = "2002",
month = "5",
doi = "10.1097/00004872-200212000-00001",
language = "English (US)",
volume = "20",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Evidence-based medicine and treatment of hypertension in women

T2 - Results of trials

AU - Hayes, Sharonne N.

PY - 2002/5

Y1 - 2002/5

N2 - Purpose: The aim of this review is to summarize the evidence from randomized controlled trials and meta-analyses of hypertension treatment trials that included women in their study population and subsequent analyses. Results: Most early hypertension treatment trials did not include women in their study population, or did so in insufficient numbers to assess gender-specific outcomes. Women, particularly the elderly, were better represented in subsequent studies, but gender-specific results were not often reported and most trials were not designed or powered to detect gender differences in treatment responses and outcomes. In some studies where gender-specific results have been reported, gender differences have been observed, but the direction of the effect has generally been similar in men and women. Large meta-analyses of treatment trials have found similar relative risk reductions as a result of hypertension treatment, but lower absolute risk reductions in women compared to men. Absolute risk reductions are strongly related to baseline risk and have been demonstrated in virtually all subgroups of women except those with extremely low aggregate cardiovascular risk. While there are still limited data regarding treatment benefits for young women, no subset of women has been shown to experience net harm as a result of hypertension therapy. Conclusion: The design and implementation of future hypertension treatment trials should include the provision to assess gender-specific differences in treatment and outcomes.

AB - Purpose: The aim of this review is to summarize the evidence from randomized controlled trials and meta-analyses of hypertension treatment trials that included women in their study population and subsequent analyses. Results: Most early hypertension treatment trials did not include women in their study population, or did so in insufficient numbers to assess gender-specific outcomes. Women, particularly the elderly, were better represented in subsequent studies, but gender-specific results were not often reported and most trials were not designed or powered to detect gender differences in treatment responses and outcomes. In some studies where gender-specific results have been reported, gender differences have been observed, but the direction of the effect has generally been similar in men and women. Large meta-analyses of treatment trials have found similar relative risk reductions as a result of hypertension treatment, but lower absolute risk reductions in women compared to men. Absolute risk reductions are strongly related to baseline risk and have been demonstrated in virtually all subgroups of women except those with extremely low aggregate cardiovascular risk. While there are still limited data regarding treatment benefits for young women, no subset of women has been shown to experience net harm as a result of hypertension therapy. Conclusion: The design and implementation of future hypertension treatment trials should include the provision to assess gender-specific differences in treatment and outcomes.

KW - Cardiovascular risk

KW - Gender

KW - Hypertension

KW - Meta-analysis

KW - Randomized control trial

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=0036563334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036563334&partnerID=8YFLogxK

U2 - 10.1097/00004872-200212000-00001

DO - 10.1097/00004872-200212000-00001

M3 - Article

C2 - 12183852

AN - SCOPUS:0036563334

VL - 20

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - SUPPL. 2

ER -